- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02071875
Comparing the Nautilus NeuroWaveTM to TCD or DSA for the Detection of Vasospasm
A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler or DSA as an Aid to Diagnosing Vasospasm
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, comparative, non-randomized study in subjects with subarachnoid hemorrhage who are undergoing surveillance for vasospasm. The study will be conducted in one center.
The primary objective of Phase I of this non-significant risk study is proof of principle. During this phase the goal is to build a library of Jan Medical NNW system recordings from patients with moderate and severe vasospasms. A signature for detecting vasospasms will be developed using the signals from a vasospasm epoch to a patient's individual baseline recording and confirming the presence of vasospasm by comparison of Jan Medical NNW system data to TCD and, when available Digital Subtraction Angiography (DSA). The number of patients required for Phase I is estimated to be 20 patients with confirmed moderate or severe vasospasm with a minimum of 10 these patients having at least one severe vasospasm recording confirmed by TCD or DSA. Daily recordings are to be taken.
During Phase II the Jan Medical NNW system will independently utilize the signatures identified in Phase I to identify the presence or absence of moderate and severe vasospasm in a blinded recording. This recording will be compared to TCD or DSA, when DSA is available, for analysis of sensitivity and specificity. Up to 50 subjects will be enrolled in Phase II. When possible, multiple recordings will be obtained from each subject to include recordings with and without vasospasm.
Duration of each subject's enrollment in this study is limited to the period of time when Jan Medical NNW system recordings are performed. No additional tests or procedures will be performed during participation in this study and all other data collected (including TCD or DSA) will be based on available evaluations conducted as part of the patient's standard of care. Upon completing the last Jan Medical NNW system recording or when no further data collection is expected, the subject will be exited from the study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
- University Medical Center of the Johannes Gutenberg University Mainz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female subjects 18 years of age or older.
- Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.
- Signed informed consent from the patient or the patient's Legally Authorized Representative
Exclusion Criteria:
- Unstable medical illness such that recordings might interfere with medical care.
- Presence of head bandages or brain monitors that might physically interfere with the NNW recording device.
- Current hemicraniectomy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nautilus NeuroWaveTM recording
Nautilus NeuroWaveTM recording 15 minute recording
|
Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity (moderate or severe)
Time Frame: Within 5 minutes from end of recording
|
Efficacy at identifying moderate or severe vasospasm.
Reference diagnosis will be with TCD and where available DSA
|
Within 5 minutes from end of recording
|
Specificity
Time Frame: Within 5 minutes of recording
|
Rate of false positives using TCD and where available DSA as the reference standard.
False positive is a recording judged mild or no vasospasm by TCD or DSA that is determined by the NNW as moderate or severe
|
Within 5 minutes of recording
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity at detecting any vasospasm
Time Frame: Within 5 minutes of recording
|
Efficacy at identifying vasospasm either mild, moderate or severe.
Reference standard will be TCD and DSA where available.
|
Within 5 minutes of recording
|
Specificity
Time Frame: Within 5 minutes of end of recording
|
Rate of false positives using TCD and where available DSA as the reference standard.
False positive is a recording determined as no vasospasm by TCD or DSA that is determined by the NNW as either mild, moderate or severe vasospasm
|
Within 5 minutes of end of recording
|
Location of vasospasm
Time Frame: Within 5 minutes of recording
|
With TCD and DSA, when available, as reference standards, the efficacy at locating any vasospasm as ocurring in the left, right or back of the cranium.
The measure will be what % of correctly called vasospasm was correctly located.
|
Within 5 minutes of recording
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of device related adverse events
Time Frame: Within 1 week of end of recording
|
The total number of adverse events reported by the clinical site
|
Within 1 week of end of recording
|
Ease of use
Time Frame: Within 5 minutes from end of recording
|
Number of recordings that were not of adequate quality for a determination.
This will be a no call
|
Within 5 minutes from end of recording
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Axel Neulen, MD, University Medical Center of the Johannes Gutenberg University Mainz
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NMDCL100212-OCA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasospasm
-
The University of Texas Health Science Center,...CompletedAnesthesia | Pediatrics | VasospasmUnited States
-
University of WashingtonTerminated
-
Johann Wolfgang Goethe University HospitalUnknownCerebral Vasospasm After Subarachnoid HemorrhageGermany
-
University of Wisconsin, MadisonCompletedSubarachnoid Hemorrhage, Aneurysmal | Vasospasm, CerebralUnited States
-
Jan Medical, Inc.CompletedCerebral VasospasmUnited States
-
University of Massachusetts, WorcesterMassachusetts General HospitalCompletedCerebral Vasospasm After Subarachnoid HemorrhageUnited States
-
VesalioCompletedCerebral VasospasmUnited States
-
Mayo ClinicWithdrawnCerebral Vasospasm
-
University of FloridaTerminated
-
University Hospital, AntwerpRecruitingCoronary Microvascular Dysfunction | Coronary Artery VasospasmBelgium
Clinical Trials on Nautilus NeuroWaveTM recording
-
Jan Medical, Inc.University of California, San FranciscoCompletedAlzheimer Disease | Mild Cognitive Impairment | Frontotemporal Lobar Degeneration | Memory DisordersUnited States
-
Jan Medical, Inc.TerminatedIschemic StrokeUnited States
-
Jan Medical, Inc.Completed
-
Jan Medical, Inc.Completed
-
Jan Medical, Inc.Completed
-
EndoStream MedicalCompleted
-
EndoStream MedicalRecruitingRuptured Cerebral AneurysmUnited States
-
Jan Medical, Inc.CompletedCerebral VasospasmUnited States
-
Coloplast A/SCompletedUrinary IncontinenceUnited States
-
University of California, San FranciscoConquer Cancer FoundationActive, not recruitingProstate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States